Gain Therapeutics, Inc. reports promising results from its Phase 1 trial of GT-02287, a novel therapy for GBA1 Parkinson’s disease. The study indicates the therapy is safe and well-tolerated, enhancing GCase enzyme function, which is pivotal in combating the disease’s progression.
Meet Gain Therapeutics’ New Chief Medical Officer: Dr Jonas Hannestad, MD, PhD
This blog discusses Parkinson’s Disease, highlighting its history, characteristics, and ongoing research. Initiatives like the PD GENEration study offer free genetic testing. Gain Therapeutics is developing GT-02287, a potential disease-modifying drug for GBA1-Parkinson’s, with support from prominent foundations and currently conducting clinical trials.
Explore the innovative world of Gain Therapeutics in this engaging fireside chat held by Lou Basenese and Jeb Terry at the recent Public Ventures Discovery Day event. Delve into how we are revolutionizing the treatment of neurodegenerative diseases, including Parkinson’s, with our next-generation Magellanᵀᴹ platform. Gain harnesses AI and physics-based methods to develop best-in-class small molecules for disorders with high unmet medical needs. Hear about the significant strides we’ve made from current Board Member and former Gain CEO Eric Richman. A must-watch for those interested in the intersection of biotechnology, AI, and healthcare advancements.
Analyzing data from Genome Wide Association Studies (GWAS) and drawing from the insights of the PD GENEration Study, Dr. Alcalay unveils the significance of glucocerebrosidase (GBA) mutations in Parkinson’s. Discover why GBA emerges as a prime target for therapeutic interventions, offering hope for tailored treatments and improved patient outcomes.
Professor Outeiro provides an in-depth exploration of Parkinson’s disease from the perspective of a seasoned basic scientist. Covering topics ranging from disease complexity and classification to emerging biomarkers and therapeutic strategies, he delves into the intricacies of Parkinson’s research, highlighting the challenges faced by scientists and clinicians alike.
Joanne Taylor highlights the groundbreaking work of Gain Therapeutics in developing GT-02287, a GBA modulator, as a potential treatment for Parkinson’s disease. She discusses the origin of GT-02287, its mechanism of action, and preclinical findings demonstrating its efficacy in addressing key pathological features of Parkinson’s disease.
What Makes a Truly Valuable AI Drug Discovery Platform? The value in AI drug discovery platforms lies in their ability to target known, yet previously
Gain Therapeutics is ready to share the latest R&D update on Parkinson’s Disease. This event is intended for all KOL’s, Analysts, Patient Advocates, and investors
Watch the video from 50 sec onwards to learn hear about Gain Therapeutics Gain Therapeutics was mentioned on Fox Business News as a company to
Beatriz Calvo-Flores Guzman, presented at the 20th Annual WORLDSymposium discussing preclinical data demonstrating that our clinical-stage GCase regulator provided neuroprotection & restored motor function in
This webinar, hosted by Force Family Office, features Gain Therapeutics, a biotech company developing treatments for Parkinson’s disease and other neurodegenerative diseases. The speakers are
Gain Therapeutics will be attending JP Morgan HealthCare Conference Jan 8th to 11th, 2024 in San Francisco. Representing will be: CEO Matthias Alder CFO Evan
“The published data propose that strategies to alleviate dysfunction such as targeting GCase could be a new therapeutic opportunity for neurodegenerative diseases and lysosomal storage
Gain’s Clinical Candidate GT-02287 Earlier this month, Gain Therapeutics announced the dosing of the first two subjects in a Phase 1 clinical trial of GT-02287,
In an engaging interview, journalist Jane King from LilaMax Media discusses cutting-edge allosteric therapies with Gain Therapeutics’ CEO, Matthias Alder, and their potential in
Biomarkers allow clinicians to measure the effects of treatment, helping determine how patients respond to therapeutic intervention. While biomarkers have been crucial in diseases such
Neurofilament light chain (NfL) is a protein found inside neurons in the brain. If axons die, for example, due to disease, NfL is released from
On the topic of standards and regulations, what has it been like to work with regulatory agencies such as the FDA and EMA (European Medicines
“Data! Data! Data! I can’t make bricks without clay.” This famous quote from Sherlock Holmes summarizes Dr. Terenzio Ignoni’s outlook on the future of drug
Give him the data, give him the facts, and Dr. Terenzio Ignoni will run with them. As the SVP of Technical Operations, Terenzio is in
We’re back with Ana Maria Garcia-Collazo, Ph.D. of Gain Therapeutics. We ended Part 1 of our interview talking about the intersection of chemistry and computational
Wisdom is not hard to come by. Passion and enthusiasm are a different story. On a bright and sunny Thursday morning in April 2023, Ana
Part 2: When we left off speaking to Evan Ballantyne, Gain Therapeutics’ new CFO, he was sharing several stories about industry and career successes. Part
On March 29th 2023, Hartaj Singh (Oppenheimer Senior Research Biotechnology Analyst) moderated a virtual Fireside Chat panel with Xavier Barril, Ph.D. (Gain Therapeutics’ CTO), Brandon
On April 12, 2023, Gain Therapeutics announced Evan Ballantyne as the company’s new Chief Financial Officer. Ballantyne has been around the block. His humble demeanor
On Thursday, April 13, 2023, The Michael J. Fox Foundation (MJFF) announced a historic breakthrough1 in the development of Parkinson’s disease detection and diagnosis. The
Over 200 years ago, Dr. James Parkinson, a neurologist, geologist, and activist, published “An Essay on the Shaking Palsy” in 1817 which described the disease.
Download : AD PD Infographic
©2022 Gain Therapeutics, Inc
